Taletrectinib clinical trials
Also written AB-106 and DS-6051b.
How each study uses taletrectinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the taletrectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 11 Jun 2025 · IBTROZI · NDA 219713 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 1
Nuvation Bio Inc. (9) · Daiichi Sankyo Co., Ltd. (1) · Megan Kruse, MD (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test taletrectinib.
- Feb 2027Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibPhase 1 · Nuvation Bio Inc.
Studies
Open first, then newest update. How each study uses taletrectinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNot yet recruitingPhase 1Nuvation Bio Inc.NCT07742384Written as Taletrectinib
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingPhase 3Nuvation Bio Inc.NCT07154706Written as Taletrectinib
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingPhase 3Nuvation Bio Inc.NCT06564324Written as Taletrectinib
- Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)SuspendedPhase 2Megan Kruse, MDNCT06214793Written as Taletrectinib
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingPhase 2Nuvation Bio Inc.NCT04395677Written as AB-106
- Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionTerminatedPhase 2Nuvation Bio Inc.NCT04617054Written as AB-106
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCActive, not recruitingPhase 2Nuvation Bio Inc.NCT04919811Written as Taletrectinib
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bCompletedPhase 1Nuvation Bio Inc.NCT02279433Written as DS6051b
- Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT02675491Written as DS-6051b
- A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKCompletedPhase 1Nuvation Bio Inc.NCT05357820Written as AB-106, Itraconazole
- A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinCompletedPhase 1Nuvation Bio Inc.NCT05357911Written as AB-106, digoxin
Codes
What other systems call taletrectinib · ClinicalTrials.gg INT001753
- MeSH (NLM) C000720459taletrectinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) W4141180YDTALETRECTINIBConfirmed FDA, NLM
- NCI Thesaurus C118948TaletrectinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720459 | taletrectinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | W4141180YD | TALETRECTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C118948 | Taletrectinib | One source FDA |
Also registered as taletrectinib adipate (UNII 6KLL51GNBG).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.